Navigation Links
Barr Confirms Patent Challenge of Entocort(R), 3mg Enteric Coated Capsules
Date:5/27/2008

MONTVALE, N.J., May 27 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by AstraZeneca LP in connection with its Entocort(R) Enteric Coated Capsules (budesonide), 3mg. The Company believes that it is the first to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for Entocort EC.

Barr filed its ANDA containing a paragraph IV certification for a generic Entocort EC product with the U.S. Food & Drug Administration (FDA) in January 2008. Following receipt of the notice from the FDA that Barr's ANDA had been accepted for filing, Barr notified the New Drug Application (NDA) and patent holder.

On May 22, 2008, AstraZeneca filed suit in the U.S. District Court for the District of Delaware to prevent Barr from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

Entocort EC (budesonide) had annual sales of approximately $125 million in the U.S., based on IMS sales data for the twelve-month period ending March 2008.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 120 generic and 27 proprietary produ
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Kiwa Bio-Tech Confirms Joint Venture Agreement With Shijiazhuang Huaxing Animal Medicine Co., Ltd.
2. Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty
3. Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients
4. U.S. Patent Office Confirms Validity of Osteotechs U.S. Patent No. 5,676,146
5. Research Confirms Better Oil from New DuPont High Oleic Soybean Trait
6. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
7. PPD Confirms Takedas NDA Filing of Alogliptin with U.S. Food and Drug Administration
8. Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
9. Icahn Confirms Intention to Nominate Three Directors at Biogen
10. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
11. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014  PAREXEL International Corporation (NASDAQ: ... presenting at the Baird Healthcare Conference in New York.  ... Financial Officer, will be making a presentation on PAREXEL ... Wednesday, Sept. 3, 2014. A live webcast ... section of PAREXEL,s website at www.PAREXEL.com in ...
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
(Date:8/20/2014)... nerves in your ear could improve the health of ... the University of Leeds used a standard TENS machine ... electrical pulses to the tragus, the small raised flap ... of the ear canal. , The stimulation changed the ... reducing the nervous signals that can drive failing hearts ...
(Date:8/20/2014)... August 20, 2014 GraphDB™ ... today including improvements to the enterprise replication cluster, ... for Lucene, SOLR and Elasticsearch. This release happens ... high performance triplestore – GraphDB™ was formerly known ... deploying the only mature enterprise resilient RDF triplestore ...
Breaking Biology Technology:PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... RICHMOND, Virginia, ROSH HA,AYIN, Israel, June 16 ,EnzySurge ... advanced,chronic wound management, recently announced the formation of ... and practitioners with diversified expertise in chronic wounds.,The ... MD, PhD, Diane L.,Krasner, PhD RN, FAAN, Joseph ...
... June 16 Alexandria Real Estate,Equities, Inc. (NYSE: ... 100 life science,executives from around the world on ... environmentally sustainable operations in the San Diego life,science ... being held in,conjunction with the Biotechnology Industry Organization,s ...
... data management product for the, hospital ... connection, BOTHELL, Wash., June 16 Cardiac ... flagship HeartCentrix(R) data,management product for the hospital market. ... across all facilities within a,hospital network. Cardiac Science ...
Cached Biology Technology:EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 2EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 3EnzySurge, Maker of DermaStream(TM), Announces the Formation of its Scientific Advisory Board 4Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 2Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 3Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO 4Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 2Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 3Cardiac Science Launches 'Anywhere' Data Management for HIS and EMR Systems 4
(Date:8/20/2014)... screening outcomes of approximately 3 million infants, a team ... the University of Massachusetts Medical School, have shown that ... successfully implemented across public health newborn screening programs. Data ... 20 issue of the Journal of the American ... of SCID in newborns is higher than previously thought ...
(Date:8/20/2014)... has awarded the Oklahoma Medical Research Foundation a five-year, ... and the bacteria,s effects on humans. , For ... colleagues have studied the human immune response to anthrax ... Immunology. The original funding came soon after anthrax-laced letters ... the terrorist attacks of Sept. 11, 2001. , ...
(Date:8/20/2014)... EUGENE, Ore. -- When are athletes who have suffered ... of Oregon study has found that high school athletes ... within 60 days experience a significant regression in their ... , The regression, as seen in changes in their ... of 19 athletes. Ten of the 12 had returned ...
Breaking Biology News(10 mins):Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3$14.5 million grant awarded to continue anthrax studies 2Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... effects of antioxidants such as vitamin C. Scientists at ... of lipid the ability of antioxidants, such as ascorbic ... against the generation of potential cancer-forming compounds in the ... “Our results illustrate how diet can influence gastric biochemistry? ...
... differs from other individuals, the level at which those ... person to another, scientists have learned. And though some ... different populations ?Asians versus Europeans, for instance ?more of ... the biological meaning of "race." , The findings ...
... Al Gore's film, An Inconvenient Truth, has generated greater ... the more rapid warming that has occurred within major ... 10 degrees hotter than their surroundings. These metropolitan hot ... can stress the animals and plants that make their ...
Cached Biology News:Individuals and populations differ in gene activity levels, not just genes 2City ants take the heat 2
... MultiScribe Reverse Transcriptase is a recombinant ... transcriptase. MultiScribe Reverse Transcriptase is similar ... in its recommended usage. MuLV reverse ... polymerase that uses single-stranded RNA as ...
... determination of digitonin and digoxin. Physical form: Lyophilized ... and 0.06% NaCl Preparation Note: Sodium iodide ... Res. Commun., 19, 755 (1965). Unit Definition: ... phosphorus from ATP per min at pH 7.4 ...
... protease from human rhinovirus (HRV 3C) is ... line of restriction grade proteases. The recombinant ... protein, which recognizes the same cleavage site ... 22 KDa size of the protease, optimal ...
... IEC Centra CL3 series is designed ... research and clinical applications at a ... package includes quick connect rotors and ... yet intuitive interface allows you to ...
Biology Products: